NASDAQ : LTGO

Latigo Biotherapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 15.54 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.03B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.

Details

NameLatigo Biotherapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees66
Founded2018
Ipo Date2026-08-07
CeoNima Farzan
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price18.00
IsinUS5179541033
Cusip517954103
Cik2056611
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Nima Farzan M.B.A.Chief Executive Officer, President and Director
Neha KrishnamohanChief Business Officer and Chief Financial Officer
Dr. Neil Kumar Singla M.D.Chief Medical Officer
Julia ChapmanSenior Vice President of Operations
Caroline DoughertyVice President of Corporate Development
Bryan Moyer Ph.D.Senior Vice President of Discovery
Polina German Pharm.D.Senior Vice President of Clinical Pharmacology and Translational
Sabrina NiederVice President and Corporate Controller
Vicki HollowaySecretary

Contact

Address1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, California 91320, United States
Phone805 716 2927
Websitehttps://latigobio.com